|
|
Article: A Different Type Of Off-Shoring To Produce Therapeutic Proteins.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Science Editor
From Genentech Inc.'s Avastin to Biogen Idec Inc.'s Zevalin, nearly twenty FDA-approved monoclonal antibodies are currently used to treat patients in various indications.
Add that to the more than 100 that are in the industry's pipeline, and they add up to one thing. Well, two things, actually: better medications, hopefully, but also an intensifying monoclonal antibody production crunch for sure.
"The problem around current production is getting more acute. And there is a massive bolus of products marching through clinical development that will lead to production shortages," Bruce Steel told BioWorld Today.
Steel is CEO ...